Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 58

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 16
Chunk 58
---
 reviews and evaluates net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. Our CODM does not evaluate the operating segment using asset or liability information. The operating segment derives all net product revenues from the sales of OJEMDA in the United States through contractual arrangements with its specialty pharmacy and specialty distributor customers. All the Company’s assets are located in the United States.In addition to the significant expense categories included within net loss presented on the Company's Statements of Operations, see below for disaggregated amounts that comprise research and development expenses:

        Year EndedDecember 31,

        2024

        2023

        2022

        (in thousands)

        External costs:

        Third-party CRO, CMO and other third-party clinical trial costs (1)
         
        $
        89,400

        $
        71,294

        $
        50,175

        License upfront payments and milestones

        80,000

        8,000

        2,500

        Other research and development costs

        8,949

        8,465

        3,598

        Internal costs:

        Employee related expenses

        49,353

        42,762

        29,345

        Total research and development expenses
         
        $
        227,702

        $
        130,521

        $
        85,618

      (1) Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.

F-36